Cart  

No products

Shipping 0,00 €
Total 0,00 €

Cart Check out

Manufacturers

Search

FORTEKOR ® 5mg 140 pills box

FORTEKOR ® 5mg 140 pills box
FORTEKOR is indicated for the treatment of congestive heart failure in dogs and reduction of proteinuria associated with chronic kidney disease in cats. Precription required. Please send a message of your prescription using contact button and attach your digitalization or photo of your prescription.

More details

On sale! 85,95 €

Add to cart

Presentation

Fortekor Flavour 5 mg.

Beige to light brown, ovaloid, divisible, tablet scored on both sides.

The tablets can be divided into equal halves.

5 mg benazepril hydrochloride.

Uses

FORTEKOR is indicated for the treatment of congestive heart failure in dogs and reduction of proteinuria associated with chronic kidney disease in cats. The active ingredient is benazepril hydro- chloride. After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly and decline quickly as the active substance is partially metabolised by liver enzymes to benazepri- lat, a highly specific and potent angiotensin convert- ing enzyme (ACE) inhibitor. Benazaprilat inhibits the conversion of inactive angiotensin I into active angio- tensin II and thereby also reduces the synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasocon- striction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).

In dogs with congestive heart failure, FORTEKOR reduces the blood pressure and volume load on the heart. Benazeprilat is excreted 54% by the biliary and

46% via the urinary route in dogs and 85% via the biliary and 15% via the urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of the dose of FORTEKOR is necessary in either species in cases of renal insufficiency.

In cats with chronic kidney disease, Fortekor signif- icantly reduces the levels of urine protein and urine protein to creatinine ratio (UPC); this effect is proba- bly mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. However, no effect of FORTEKOR on survival in cats with CKD has been shown. FORTEKOR has also been shown to increase the appetite of cats, particularly in more advanced cases.

Dosage and administration

FORTEKOR Flavour should be given orally once daily, with or without food. The duration of treatment is unlimited. FORTE- KOR Flavour 5 mg tablets are flavoured and are taken voluntarily by most dogs and cats.

Dogs: Fortekor should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride / kg bodyweight once daily.

The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon. FORTEKOR Flavour has been given in combination with digoxin, diuretics, pimo- bendan and anti-arrhythmic veterinary products with- out demonstrable adverse interactions.

Cats: FORTEKOR Flavour should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight.

Contra-indications, warnings, etc

Do not use during pregnancy or lactation. The safety of FORTEKOR has not been established in breeding, pregnant or lactat- ing dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.

Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.

The efficacy and safety of FORTEKOR has not been established in dogs and cats below 2.5 kg body weight.

For animal treatment only. For oral use only. Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting en- zyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

In double-blind clinical trials in dogs with conges- tive heart failure, FORTEKOR was well tolerated with an incidence of adverse reactions lower than ob- served in placebo-treated dogs. No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials. However, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creati- nine, urea and erythrocyte counts during therapy.

A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.

In cats and dogs with chronic kidney disease, FORTEKOR may increase plasma creatinine concen- trations at the start of therapy. A moderate increase in plasma creatinine concentrations following admin- istration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

FORTEKOR may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.

In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of FORTEKOR and other anti-hypertensive agents (e.g. calcium channel blockers, beta-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medi- cations with a hypotensive effect should be consid- ered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary.

Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using FORTEKOR in combi- nation with a potassium sparing diuretic because of the risk of hyperkalaemia.

Pharmaceutical precautions

Do not store above 25˚C.

Each time an unused half tablet is stored, it should be returned to the open blister space, inserted back into the cardboard box and kept in a safe place out of the reach and sight of children. Tablet halves should be used within 2 days.

No customer comments for the moment.

Only registered users can post a new comment.